AU2007317859B2 - Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer - Google Patents

Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer Download PDF

Info

Publication number
AU2007317859B2
AU2007317859B2 AU2007317859A AU2007317859A AU2007317859B2 AU 2007317859 B2 AU2007317859 B2 AU 2007317859B2 AU 2007317859 A AU2007317859 A AU 2007317859A AU 2007317859 A AU2007317859 A AU 2007317859A AU 2007317859 B2 AU2007317859 B2 AU 2007317859B2
Authority
AU
Australia
Prior art keywords
variations
taxane
effective amount
individual
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007317859A
Other languages
English (en)
Other versions
AU2007317859A1 (en
Inventor
Neil P. Desai
Patrick Soon-Shiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of AU2007317859A1 publication Critical patent/AU2007317859A1/en
Priority to AU2013204181A priority Critical patent/AU2013204181A1/en
Application granted granted Critical
Publication of AU2007317859B2 publication Critical patent/AU2007317859B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007317859A 2006-11-06 2007-11-06 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer Active AU2007317859B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204181A AU2013204181A1 (en) 2006-11-06 2013-04-12 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/594,417 US20070166388A1 (en) 2005-02-18 2006-11-06 Combinations and modes of administration of therapeutic agents and combination therapy
US11/594,417 2006-11-06
PCT/US2007/023446 WO2008057562A1 (en) 2006-11-06 2007-11-06 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013204181A Division AU2013204181A1 (en) 2006-11-06 2013-04-12 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Publications (2)

Publication Number Publication Date
AU2007317859A1 AU2007317859A1 (en) 2008-05-15
AU2007317859B2 true AU2007317859B2 (en) 2013-07-25

Family

ID=39111840

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007317859A Active AU2007317859B2 (en) 2006-11-06 2007-11-06 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Country Status (22)

Country Link
US (1) US20070166388A1 (Direct)
EP (3) EP3108885A1 (Direct)
JP (3) JP5931323B2 (Direct)
KR (4) KR20090087906A (Direct)
CN (2) CN101573108A (Direct)
AU (1) AU2007317859B2 (Direct)
BR (1) BRPI0718528A2 (Direct)
CA (1) CA2668607A1 (Direct)
CY (2) CY1115271T1 (Direct)
DK (2) DK2097078T3 (Direct)
ES (2) ES2576289T3 (Direct)
HU (1) HUE028472T2 (Direct)
IL (2) IL198576A (Direct)
MX (1) MX2009004803A (Direct)
NO (1) NO343908B1 (Direct)
NZ (1) NZ576856A (Direct)
PL (2) PL2097078T3 (Direct)
PT (2) PT2481405E (Direct)
RU (2) RU2009121568A (Direct)
SI (2) SI2097078T1 (Direct)
WO (1) WO2008057562A1 (Direct)
ZA (1) ZA200903132B (Direct)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
KR100789008B1 (ko) * 1997-06-27 2007-12-26 아브락시스 바이오사이언스 인크. 신규 약물 제제
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX383644B (es) * 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
JP5368093B2 (ja) * 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CA2653756A1 (en) * 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CA2679859A1 (en) * 2006-11-01 2008-05-15 George Mason Intellectual Properties, Inc. Method for detecting and controlling cancer
EP2117520B1 (en) 2006-12-14 2018-08-29 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
EP2170319A4 (en) * 2007-06-22 2011-10-12 Scidose Llc SOLVENT FORMULATION FROM DOCETAXEL WITHOUT TWEEN 80
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2310006A4 (en) 2008-07-03 2012-04-25 Mayo Foundation CANCER TREATMENT
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
ES2528032T3 (es) * 2009-01-16 2015-02-03 Rigel Pharmaceuticals, Inc. Inhibidores de Axl para su uso en terapia de combinación para prevenir, tratar o manejar cáncer metastásico
JP5725563B2 (ja) * 2009-03-13 2015-05-27 アブラクシス バイオサイエンス， エルエルシー チオコルヒチン誘導体との組み合わせ療法
EP3626233A1 (en) 2009-04-15 2020-03-25 Abraxis BioScience, LLC Prion-free nanoparticle compositions and methods
JP2012532879A (ja) * 2009-07-07 2012-12-20 ノームオキシーズ，インコーポレイテッド イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
RU2012140447A (ru) * 2010-02-23 2014-03-27 Дженентек, Инк. Антиангиогенная терапия для лечения рака яичника
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
KR20180050426A (ko) * 2010-03-29 2018-05-14 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
CA2801645A1 (en) 2010-06-04 2011-12-08 Abraxis Bioscience, Llc Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer
RU2016103126A (ru) * 2010-06-07 2018-11-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы комбинированной терапии для лечения пролиферативных заболеваний
US20120121510A1 (en) * 2010-11-11 2012-05-17 Brem Rachel F Localized therapy following breast cancer surgery
WO2012068098A1 (en) * 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
TWI558401B (zh) 2011-11-01 2016-11-21 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
KR20140107417A (ko) 2011-12-14 2014-09-04 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
CA2860941C (en) * 2012-03-13 2019-11-05 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
HK1218506A1 (zh) * 2013-02-11 2017-02-24 阿布拉科斯生物科学有限公司 治療黑素瘤的方法
WO2014159171A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
US10842969B2 (en) 2013-10-25 2020-11-24 Mercator Medsystems, Inc. Systems and methods of treating malacia by local delivery of hydrogel to augment tissue
WO2015134543A1 (en) * 2014-03-05 2015-09-11 Sorrento Therapeutics, Inc. Pharmacokinetically equivalent nanoparticle compositions
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
CN104434808A (zh) * 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
BR112016030965A2 (pt) * 2014-10-06 2017-08-22 Mayo Found Medical Education & Res Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
HUE070408T2 (hu) 2015-06-29 2025-06-28 Abraxis Bioscience Llc Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra
JP6921802B2 (ja) * 2015-08-18 2021-08-18 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ キャリア結合剤組成物およびそれを作製および使用する方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
WO2017176265A1 (en) * 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105288639A (zh) * 2015-11-23 2016-02-03 中国药科大学 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
WO2017139698A1 (en) * 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR102482503B1 (ko) * 2016-08-05 2022-12-30 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료를 위한 변형된 항체-알부민 나노입자 복합체
US11406684B2 (en) * 2016-08-26 2022-08-09 Tetsuji Okuno Fine nano-sized medicinal agent and use thereof
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
RU2019109209A (ru) 2016-09-01 2020-10-05 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
JP2019526587A (ja) 2016-09-06 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｐｄ−ｌ１を発現する癌を処置する方法
CN106310291A (zh) * 2016-09-14 2017-01-11 东南大学 主动靶向抗肿瘤纳米药物及其制备方法和应用
LT3532059T (lt) 2016-10-27 2022-05-25 Celgene Quanticel Research, Inc. Bromodomeno ir papildomo galinio baltymo inhibitorių derinio terapija
WO2018081652A2 (en) * 2016-10-28 2018-05-03 Nant Holdings Ip, Llc Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
BR112020009055A2 (pt) 2017-11-06 2020-11-03 Rapt Therapeutics, Inc. moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr
WO2019104042A1 (en) * 2017-11-21 2019-05-31 University Of Iowa Research Foundation Synthetically lethal nanoparticles for treatment of cancers
AU2018388579A1 (en) * 2017-12-19 2020-07-09 Abraxis Bioscience, Llc Methods of treating colon cancer using nanoparticle mTOR inhibitor combination therapy
WO2019147944A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
KR102263606B1 (ko) 2020-02-11 2021-06-10 충북대학교 산학협력단 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135486A1 (en) * 2004-09-13 2006-06-22 Eisai Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CZ333796A3 (cs) 1991-03-06 1998-06-17 MERCK Patent Gesellschaft mit beschränkter Haftung Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
EP0739203A4 (en) 1994-01-14 2000-12-20 Cell Therapeutics Inc METHOD OF TREATING CELL PROLIFERATION CONDITIONS IN RESPONSE TO PDGF, EGF, FGF AND VEGF
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
ATE350048T1 (de) 1998-04-16 2007-01-15 Eurovita As Neue synergistische zusammensetzungen, die aromatische verbindungen und in alpinia galanga vorhandene terpenoide enthalten
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US20050186208A1 (en) * 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CN1856327A (zh) * 2003-09-23 2006-11-01 诺瓦提斯公司 Vegf受体抑制剂与化疗剂的组合
US20060003931A1 (en) 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
MX2007008810A (es) * 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
KR20070114774A (ko) * 2005-02-28 2007-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 혈관 신생 저해 물질과의 신규 병용
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP5368093B2 (ja) * 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135486A1 (en) * 2004-09-13 2006-06-22 Eisai Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy

Also Published As

Publication number Publication date
MX2009004803A (es) 2009-07-09
SI2481405T1 (sl) 2016-08-31
EP2097078B1 (en) 2014-04-16
EP3108885A1 (en) 2016-12-28
WO2008057562A1 (en) 2008-05-15
PT2481405E (pt) 2016-06-08
JP2016014073A (ja) 2016-01-28
NO343908B1 (no) 2019-07-01
ES2576289T3 (es) 2016-07-06
CY1117725T1 (el) 2017-05-17
KR101857142B1 (ko) 2018-05-14
RU2009121568A (ru) 2010-12-20
KR20090087906A (ko) 2009-08-18
PT2097078E (pt) 2014-07-25
ZA200903132B (en) 2010-08-25
JP2010509331A (ja) 2010-03-25
JP2014043454A (ja) 2014-03-13
US20070166388A1 (en) 2007-07-19
PL2481405T3 (pl) 2016-09-30
BRPI0718528A2 (pt) 2013-11-19
KR20180012339A (ko) 2018-02-05
CN101573108A (zh) 2009-11-04
IL198576A (en) 2016-12-29
DK2097078T3 (da) 2014-05-12
HUE028472T2 (en) 2016-12-28
DK2481405T3 (en) 2016-06-06
IL244390A (en) 2017-04-30
EP2097078A1 (en) 2009-09-09
PL2097078T3 (pl) 2014-09-30
KR20150065957A (ko) 2015-06-15
CY1115271T1 (el) 2017-01-04
HK1173976A1 (en) 2013-05-31
AU2007317859A1 (en) 2008-05-15
KR20170016017A (ko) 2017-02-10
EP2481405A1 (en) 2012-08-01
IL244390A0 (en) 2016-04-21
NO20092179L (no) 2009-08-06
ES2469716T3 (es) 2014-06-18
NZ576856A (en) 2012-06-29
SI2097078T1 (sl) 2014-07-31
RU2013149282A (ru) 2015-05-10
RU2673805C2 (ru) 2018-11-30
CA2668607A1 (en) 2008-05-15
IL198576A0 (en) 2010-02-17
CN104940929A (zh) 2015-09-30
JP5931323B2 (ja) 2016-06-08
EP2481405B1 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
AU2007317859B2 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
US20200316216A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
CA2902071C (en) Combination chemotherapy regimens using albumin/paclitaxel nanoparticles and nucleoside analogs
US20100112077A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2013204188B2 (en) Combinations and modes of administration of therapeutic agents and combination therapy
AU2013204181A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2012201568B2 (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1250006B (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1232772A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1173976B (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1134256B (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1134256A (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1155067B (en) Combinations and modes of administration of therapeutic agents and combination therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)